



कर्मचारी राज्य बीमा निगम
(श्रम एवं रोजगार मंत्रालय, भारत सरकार)
EMPLOYEES' STATE INSURANCE CORPORATION
(Ministry of Labour & Employment, Govt. of India)



मुख्यालय/HEADQUARTERS
पंचदीप भवन, सी.आई.जी. मार्ग, नई दिल्ली - 110 002
Panchdeep Bhawan, C.I.G. Marg, New Delhi-110002
www.esic.gov.in ☎ 011-23604773, ✉ dmcrc@esic.nic.in

U-25/12/Off_Patent/Deletion_RC_item/2025-MedV (E- 1217106) / Dated: 1/58

सेवा में,

Director (Medical) Delhi/Director(Medical) Noida
Deans- All PGIMSR's/Medical/Dental Colleges
Medical Superintendents-All ESI Hospitals
Dispensary Incharges- Delhi/NCR/States
Directors ESI Schemes- All State

संशोधन सं /Corrigendum-06 in DG ESIC RC NO. 162

विषय: Corrigendum in r/o DG-ESIC Rate Contract No. 162- reg.

संदर्भ: U-25/12/RC/159TO163/2022-Med.V (E-117064)/162 dtd 08.04.2025

Sir/Madam

Reference captioned subject, it is hereby informed that following below mention drugs/items have been deleted from the approved item list of DG-ESIC Central Rate Contract No.162 (valid from 08.04.2025 to 07.04.2027) :

A)

S. No.	Name of approved Pharmaceutical Firm	Item No.	Item Description	Preference	Remarks
1	M/s Boehringer Ingelheim India Private Limited	2094	Empagliflozin Tab/Cap Each film coated tab/cap to contain : Empagliflozin 10 mg Brand Name-(Jardiance® 10 mg)	1st Preference	Off-Patent
2	M/s Boehringer Ingelheim India Private Limited	2231	Empagliflozin + Linagliptin- Each Tab/Cap to contain : Empagliflozin 10 mg + Linagliptin 5 mg Brand Name- GLYXAMBI® 5/10 mg	1st Preference	Off-Patent

Contd. to pre-page:-

B)

S. No.	Name of approved Pharmaceutical Firm with preference	Item No.	Item Description	Remarks
1	a. M/s Hab Pharmaceuticals & Research Ltd:- L1 preference b. M/s Unicare India Ltd:- L2 preference c. M/s Overseas Health Care Private Limited:- L3 preference	2093	Metformin + Glimepiride Tab/Cap- Each Uncoated Tab/Cap to contain : Metformin Hydrochloride IP 500 mg (As a Sustained Release , Glimepiride IP 1mg.	Withdrawal/Cancellation of FDC Approval by CDSCO

This is for your information and necessary action.

This issues with the approval of Competent Authority.

Yours Sincerely

Digitally signed by

Sanjiv Kochhar

Date: 05-05-2025

Deputy Medical Commissioner (RC)

Copy to:

1. M/s Boehringer Ingelheim India Private Limited, Unit No. 202 and part of Unit no.201, 2nd Floor Godrej 2, Pirojsha Nagar, Eastern express Highway, Vikhroli (E), Mumbai-400079 (Email-pmbtender.in@boehringer-ingelheim.com, anurag.sharma@boehringer-ingelheim.com, prerana.yadav@boehringer-ingelheim.com) for information.
2. Hab Pharmaceuticals & Research Ltd, A-301, Peninsula Business park, Ganpatrao Kadam, MARG Lower Parel Mumbai-400013(Email:- marketing@habpharma.in.) for information.
3. Unicare India Ltd. , C-21,22& 23, Sector-3, Noida-, Distt -Gautan Budh Nagar , U.P.- 201301 (unicure@unicureindia.com,mkumar712@gmail.com) for information.
4. Overseas Health Care Private Limited, 33KM Milestone, National Highway No. 1, P.O. Box 25, Phillaur,Jalandhar-Punjab-144410 (E-mail: info@overseashealthcare.co.in, dmohcpl@gmail.com) for information.
5. Website Content Manager with a request to upload the same on ESIC HQ website.